相关实验视频
Updated: Sep 26, 2026

09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
15.9K
在纳米大小的药物输送系统的内管理的最新研究和进展
Wan Su Yun1, Jeongrae Kim1, Dong-Kwon Lim1
1Korea Institute of Science and Technology (KU-KIST), Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea.
Nanomaterials (Basel, Switzerland)
|August 12, 2023
概括
内纳米药物递送系统 (nanoDDSs) 通过直接向瘤,提供了改进的癌症治疗. 这种方法提高了药物的疗效,并减少了与全身药物相比的副作用.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 30年来,纳米大小的药物递送系统 (nanoDDS) 已被用于癌症治疗,利用通过增强的透性和保留效应来被动瘤向.
- 纳米DDS的系统管理面临诸多挑战,包括瘤向不足,不良的生物分布和载体毒性.
研究的目的:
- 总结了癌症治疗中内纳米DDS的近期进展.
- 为了确定增强内纳米DDS管理的治疗疗效的因素.
- 讨论内纳米DDS的实验和临床应用.
主要方法:
- 审查最近的研究和进步在内纳米DDS管理.
- 对影响治疗疗效的因素的分析.
- 讨论各种癌症疗法和临床研究中的实验结果.
主要成果:
- 内纳米DDS的使用增强了瘤特异性的治疗剂的积累和保留.
- 通过增加门内度,提高生物可用性较差的药物的疗效.
- 通过局部化交付,最大限度地减少有毒剂的全身副作用.
结论:
- 内纳米DDS的使用是改善癌症治疗的多功能策略.
- 这种方法增强了治疗效果,并减少了与纳米DDSs相关的全身毒性.
- 内输送有望在癌症治疗中得到更广泛的应用.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

